90 – Season 6 Recap & Integration (S6E15)

All right, welcome back everyone for another
deep dive. We're picking up where we left off
in season six, going back to some, you know,
some manufacturing and process development, all
those good things we were talking about before.
Yeah. Yeah. We dug pretty deep into those topics
back then. I think it's good to come back, kind
of synthesize everything, pull out the most important
takeaways. Exactly. It's like, you know, we explored
all these different paths and now it's time to
like step back. see the whole forest for the
trees, and really understand how all these pieces
connect to ensure the quality of the drugs that
people ultimately rely on. Exactly, because at
the end of the day, that's what really matters,
right? Right safe and effective medicines. Absolutely
and and for this, uh, you know for this deep
dive We're not just drawing on those season six
conversations We're also bringing in some real
world examples from the literature specifically
From oprnd organic process research and development.
That's kind of like the go -to journal for for
experts in this field Yeah, I mean that's where
you see the cutting edge of process chemistry
and engineering So it's a great resource to see
how these concepts actually play out in practice.
Right, right so Let's kind of set the stage here.
When we talk about an API, you know, the active
pharmaceutical ingredients, the actual medicinal
part of the drug, what exactly are we talking
about when we say quality? Well, when we're talking
about API quality, there are three main things
we look at. First is chemical purity. We want
to make sure that the API is as pure as possible,
meaning it contains a high percentage of the
desired molecule and very little of anything
else. Makes sense. You want the good stuff, not
a bunch of extra junk. Exactly. And then the
second thing is impurities. We need to understand
what kinds of impurities might be present, where
they come from, and how much of them is acceptable.
Because even small amounts of impurities can
potentially impact the safety and efficacy of
the drug. Right. Right. And I remember from our
previous discussions that there's usually a minimum
purity level, right? Yeah. Yeah. You typically
see a minimum purity specification around 98%.
98%. OK. And what's the logic behind that? Well,
there are a couple of reasons. First, it ensures
that when you take the medication, you're getting
a therapeutically relevant dose of the active
ingredient. And second, it helps to minimize
the risk of any unwanted effects from those impurities
we were just talking about. Got it. So it's a
balance of making sure there's enough of the
good stuff and not too much of anything that
could cause problems. Exactly. OK. So we've got
purity and impurities. What's the third thing
you mentioned? In. Oh, yes. The third aspect
of API quality is its physical attributes, things
like its color, melting point, and crystal structure.
And you might be thinking, why does that matter?
It's just a raw chemical, right? Yeah, I was
going to say, I wouldn't necessarily think about
what a chemical looks or feels like. But it turns
out these physical characteristics can have a
huge impact on the final drug product. For example,
the crystal structure of an API can affect how
easily it dissolves, which can then impact how
quickly and effectively the drug is absorbed
by the body. Huh. So if the crystal structure
is different, that could actually change how
the API behaves. when it's being turned into
a pill, for instance. Precisely. And that, in
turn, can influence how the drug is released
and absorbed in the body. So controlling these
physical attributes is just as important as ensuring
chemical purity. That's fascinating. I never
would have thought about it that way. Yeah. It's
one of those things that you don't really think
about until you start digging into the details.
Right. And all of this careful consideration
of quality, it all feeds into this bigger picture
of process development, right? Absolutely. Defining
those quality attributes is really just the first
step. Then you need to figure out how to actually
make the API and how to make it consistently
and on a large scale. And that's where process
development comes in. So you've got your target
quality defined, and now you need to develop
the actual recipe to achieve it. Especially when
we're talking about producing enough medicine
to supply everyone who needs it. Exactly. Process
development is all about scaling up the manufacturing
process from those small batches you might make
in a research lab to the large quantities needed
for commercial production. And the goal is to
do this in a way that ensures that high quality
API we were just talking about is produced consistently
and reliably. Okay. And I think we touched on
this in season six, but there are guidelines,
frameworks that help steer this process, right?
Something about ICHQ 11. You got it. ICHQ 11,
yeah, that's a key guideline from the International
Council for Harmonization. It basically provides
a framework for a science -based and risk -managed
approach to developing and manufacturing APIs.
So it's about having a strategic informed approach
rather than just like winging it. Exactly. And
it helps to ensure consistency and quality across
different manufacturers and regions. OK, that
makes sense. And what about quality by design?
I remember that being a big theme in our season
six discussions as well. It seems like that's
a very proactive way of thinking about quality.
Yeah. Quality by design or QBD is a philosophy
where you're not just testing for quality at
the end of the process. You're building it into
the process from the very beginning. So it's
like, instead of just reacting to problems, you're
trying to anticipate them and prevent them in
the first place. Exactly. And it involves a deep
understanding of the process and how different
variables can impact the final product quality.
Got it. So it's a foresighted control. Exactly.
OK. So we've got these frameworks, ICH Q11, quality
by design. And under all of this, there's this
foundational requirement of GMP. Right, good
manufacturing practice. Yes, absolutely. GMP
is essential. It encompasses all the regulations
and standards that need to be followed during
the manufacturing process to ensure the safety,
quality, and purity of the drug product. So GMP
is kind of like the ground rules, the non -negotiables
for making medicine. Precisely. And it's not
just something you check off a list. It's an
ongoing commitment to maintaining those high
standards. Okay, so you've developed this really
robust process, you've followed all the guidelines,
and now you need to, let's say, scale up production
significantly, or transfer the process to a different
manufacturing site. That's where tech transfer
comes in. Yeah, tech transfer or technology transfer
is the process of moving a manufacturing process
from one location to another, and this could
be from a research lab to a pilot plant, or from
a pilot plant to a full -scale manufacturing
facility. And that sounds like it could be a
really delicate process. It can be. It requires
careful planning, detailed documentation, and
a lot of communication between the different
teams involved. I bet. So OK, we've kind of recapped
what defines API quality, that whole journey
of process development and scale up. And we've
touched on these key frameworks in GMP. But I
think now let's really dive into the heart of
this discussion. How does all of this process
optimization actually translate to the quality
of the medicine that someone eventually takes?
And this is where I think those real -world examples
from OPRD will really come in handy. Absolutely.
Let's look at some specific cases that show this
link between process optimization and drug quality.
One example that comes to mind is a study on
purifying a compound using silica plug chromatography.
Silica plug chromatography, OK. Yeah. Now, what's
really interesting is the level of detail they
went into in describing the process. They specified
the exact composition of the elution solution,
the temperature at which the solvent was removed,
and even the criteria they used to determine
when the compound was sufficiently pure. And
all of this meticulous attention to detail led
to a very high purity API, like 99 % pure. Wow.
So by tweaking those seemingly small parameters,
they were able to significantly improve the quality
of the final product. Exactly. And they confirmed
the purity using techniques like NMR and GCMS,
which give you a really precise picture of what's
in the sample. OK, so that's a really great example
of how fine tuning a specific step can make a
big difference. What about... What about when
we're talking about a multi -step synthesis,
where you have multiple reactions happening in
sequence to make a more complex molecule? Yeah.
Multi -step synthesis can definitely be more
challenging. But again, the key is optimization
at each step. Researchers will experiment with
different reagents, temperatures, reaction times,
and workup procedures to find the optimal conditions
for each step. And what are they optimizing for?
Is it just yield, like getting as much of the
product as possible? Well, yield is definitely
important, but it's not the only thing. They're
also trying to minimize the formation of any
unwanted byproducts, which can be impurities
in the final API. Right. So it's about both maximizing
the good stuff and minimizing the bad stuff.
Okay. And we've talked a lot about traditional
batch reactions, but I know there's been a lot
of interest in continuous flow chemistry and
technologies like micro flow reactors. Can you
talk a little bit about how those play into process
optimization and drug quality? Yeah. Continuous
flow chemistry is a really exciting area because
it offers a lot of advantages in terms of control
and efficiency. For example, let's say you have
a reaction that needs to be run at a very specific
temperature to prevent side reactions or to ensure
safety. With a continuous flow system, you can
maintain that precise temperature much more easily
than in a batch reactor. You're constantly flowing
the reactants through a controlled environment,
right? Exactly. And that level of control can
lead to more consistent product formation and
potentially fewer impurities in the final API.
So it's like you're creating a very precise miniaturized
factory for the reaction. to happen in. That's
a great analogy. Okay. And what about, I know
safety is a huge consideration in pharmaceutical
manufacturing, how does that tie into process
optimization and ultimately drug quality? Safety
is absolutely paramount and it's actually very
closely linked to quality. If a process isn't
safe, it's much more likely to have deviations
or accidents that could compromise the quality
of the product. So researchers will often go
to great lengths to design processes that are
inherently safer. Can you give an example? Sure.
Let's say a process involves using a particularly
hazardous reagent. They might look for alternative
reagents that are less hazardous, or they might
design the process in a way that minimizes the
amount of that reagent that needs to be used,
or they might use specialized equipment to handle
it safely. OK, that makes sense. So it's not
just about making the drug. It's about making
it in a way that protects the people involved
in the environment. Exactly. And what about when
a new synthetic route is developed for a particular
drug? optimization play into that? Well, when
a new route is being developed one of the key
goals is to make it as efficient and scalable
as possible. That means minimizing the number
of steps, using readily available starting materials,
and avoiding any steps that are particularly
difficult or hazardous to perform on a large
scale. So it's like streamlining the whole process,
right? Right. And that streamlining often goes
hand in hand with improvements in purity. If
you can eliminate steps that are prone to generating
impurities, then your final product is likely
to be pure. It sounds like it's all interconnected,
the efficiency, the safety, the purity. It absolutely
is. OK. We've talked about silica plug chromatography,
multi -step synthesis, continuous flow chemistry.
Are there any other examples from OPR and D that
come to mind that really highlight this link
between process optimization and drug quality?
Oh, absolutely. There are tons of examples. One
that I think is really interesting is the use
of packed bed reactors for continuous flow reactions.
Packed bed reactors. OK. Yeah. So in a packed
bed reactor, you have a tube that's filled with
a catalytic material, and the reactants flow
through the tube and react. on the surface of
the catalyst. And the key here is that by controlling
the flow rate, temperature, and pressure, you
can create a really consistent reaction environment,
which leads to more uniform product quality.
It's like that miniaturized factory idea again,
only this time it's a packed bed reactor. Exactly.
And what about impurity control? We talked about
that a little bit earlier, but are there any
specific examples that stand out? Yeah, I remember
one study where they were looking at a reaction
that produced a small amount of very specific
impurity. And by carefully studying the reaction
mechanism, they were able to figure out exactly
when and how that impurity was forming. And then
they were able to adjust the reaction conditions
to suppress its formation. Wow. So it's not just
about removing impurities after they're formed,
it's about understanding how to prevent them
from forming in the first place. Precisely. That's
the ideal scenario. And I've heard about these
things called telescope procedures. Can you explain
what those are and how they relate to process
optimization? Yeah, a telescope procedure is
where you combine multiple reaction steps into
one continuous process without isolating the
intermediate products. So instead of having multiple
separate steps with purifications in between,
you do every in one go. Exactly. And this can
be really beneficial for both efficiency and
purity. You're reducing the number of handling
steps, which can introduce impurities, and you're
often able to improve the overall yield. That's
pretty clever. Yeah, it's a really elegant approach.
And finally, what about the use of catalysts?
We haven't really talked about those much, but
I know they play a huge role in organic chemistry.
They do. And the development of new improved
catalysts is a constant area of research. One
of the main goals is to find catalysts that are
highly selective, meaning they only catalyze
the desired reaction and don't produce a lot
of side product. So a more selective catalyst
would lead to a purer product. Right. Exactly.
And it can also make the process more efficient
because you're not wasting starting materials
on unwanted reactions. Right. Right. It's like
having a more precise tool for doing the chemistry.
That's a great way to put it. Okay. So we've
covered a lot of ground here. We've seen how
process optimization, from the very specific
details of individual reactions to the overall
design of the manufacturing process, has a direct
impact on the quality of the API. And we've only
just scratched the surface, really. The OPR &D
literature is full of amazing examples of process
innovation. It's incredible to see the level
of scientific rigor and ingenuity that goes into
all of this. It really is. But we can't forget
about the final piece of the puzzle. quality
control, and process validation. It's not enough
to just develop a great process. You also need
to prove that it works consistently. Absolutely.
Quality control involves rigorous testing of
the API throughout the manufacturing process
to make sure it meets those predefined specifications
we talked about earlier. Things like purity,
impurity levels, and physical attributes. And
process validation is about demonstrating that
your manufacturing process can reliably and consistently
produce an API that meets those specifications.
And are there specific guidelines or regulations
around process validation? Oh, absolutely. ICH
Q6A, for example, provides detailed guidance
on process validation. And of course, GMP regulations
require meticulous documentation of every step
of the process to ensure traceability and accountability.
So it's not just about making a good batch of
API. It's about proving that you can do it over
and over again. Exactly. Consistency is key.
And all of this ultimately ties back to ensuring
that the medicine that reaches the patient is
safe, effective, and of the highest quality.
Precisely. That's the ultimate goal. So this
deep dive has really been a journey behind the
scenes of pharmaceutical manufacturing. We've
seen how complex and meticulous the process is,
and we've seen how every decision from the choice
of reagents to the design of the reactor can
impact the quality of the final product. And
it's a reminder that making medicines is a huge
responsibility. It is. And it's also a testament
to the incredible work that scientists and engineers
do to develop and manufacture these lifesaving
therapies. Absolutely. And with that in mind,
I think it'd be interesting to leave our listeners
with a question to ponder. You know, we've discussed
how complex drug manufacturing is, and we know
that new drug molecules are becoming increasingly
sophisticated. So what do you think are the biggest
challenges? in consistently manufacturing high
quality medicines for everyone who needs them
in this ever evolving landscape? That's a great
question. And it's something that the pharmaceutical
industry is constantly grappling with. I think
it involves finding the right balance between
scientific innovation, technological advancements,
and robust regulatory oversight. It's definitely
a multifaceted challenge. Well, that's all the
time we have for today. Thanks for joining us
for this deep dive into pharmaceutical manufacturing.
It's been a pleasure. And to our listeners. Keep
those questions coming and we'll see you next
time on the Deep Dive.